Improved liquid chromatographic tandem mass spectrometric determination and pharmacokinetic study of glimepiride in human plasma.
暂无分享,去创建一个
[1] J. Balfour,et al. Glimepiride , 1998, Drugs.
[2] I. Salem,et al. Determination of glimepiride in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[3] W. Smyth. Electrospray ionisation mass spectrometric behaviour of selected drugs and their metabolites , 2003 .
[4] F. Peters,et al. Screening, library-assisted identification and validated quantification of oral antidiabetics of the sulfonylurea-type in plasma by atmospheric pressure chemical ionization liquid chromatography-mass spectrometry. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[5] J. Goldstein,et al. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. , 2001, British journal of clinical pharmacology.
[6] P. Neuvonen,et al. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride , 2001, Clinical pharmacology and therapeutics.
[7] S. Altınöz,et al. Analysis of glimepiride by using derivative UV spectrophotometric method. , 2001, Journal of pharmaceutical and biomedical analysis.
[8] J. Miners,et al. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.
[9] A. J. Bowen,et al. Short-Term Comparison of Once- versus Twice-Daily Administration of Glimepiride in Patients with Non-Insulin-Dependent Diabetes Mellitus , 1997, The Annals of pharmacotherapy.
[10] R. Rosskamp,et al. Long-Term Treatment of Type 2 Diabetic Patients with the New Oral Antidiabetic Agent Glimepiride (Amaryl®): A Double-Blind Comparison with Glibenclamide , 1996, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[11] N. York,et al. Characterization of the Molecular Mode of Action of the Sulfonylurea, Glimepiride, at β-Cells , 1996, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[12] E. Draeger. Clinical profile of glimepiride. , 1995, Diabetes research and clinical practice.
[13] W. Waldhäusl,et al. DOSE LINEARITY ASSESSMENT OF GLIMEPIRIDE (AMARYL®) TABLETS IN HEALTHY VOLUNTEERS , 1994, Drug metabolism and drug interactions.
[14] W. Waldhäusl,et al. ABSOLUTE BIOAVAILABILITY OF GLIMEPIRIDE (AMARYL®) AFTER ORAL ADMINISTRATION , 1994, Drug metabolism and drug interactions.
[15] K. Ratheiser,et al. Dose relationship of stimulated insulin production following intravenous application of glimepiride in healthy man. , 1993, Arzneimittel-Forschung.
[16] K. Lehr,et al. Simultaneous determination of the sulphonylurea glimepiride and its metabolites in human serum and urine by high-performance liquid chromatography after pre-column derivatization. , 1990, Journal of chromatography.
[17] K. Geisen. Special pharmacology of the new sulfonylurea glimepiride. , 1988, Arzneimittel-Forschung.
[18] J. A. Scarlett,et al. The Acute and Chronic Effects of Sulfonylurea Therapy in Type II Diabetic Subjects , 1984, Diabetes.